NEW YORK, April 21, 2021 /PRNewswire/ -- Oramed
Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com),
a clinical-stage pharmaceutical company focused on the development
of oral drug delivery systems, today announced that CEO
Nadav Kidron will be featured in a
live webinar titled Grand Rounds: a Webinar in Biotech and
Specialty Pharma hosted by James
Molloy, Managing Director of Equity Research, Biotechnology
and Specialty Pharmaceuticals at Alliance Global Partners on
Monday, April 26, 2021 at 11:00
Eastern.
Mr. Kidron, along with Premas Biotech Co-Founder and Managing
Director Dr. Prabuddha Kundu, will
discuss Oramed Pharmaceuticals' oral insulin drug, currently in
Phase 3 clinical trials, and the oral COVID-19 vaccine candidate of
Oravax Medical Inc., which is 63% owned by Oramed Pharmaceuticals.
Pre-clinical trials have shown that Oravax's oral vaccine candidate
produces antibodies after a single dose and may potentially be a
better candidate for protection against COVID-19 variants due to
triple antigen targeting. Clinical trials are expected to begin
this quarter.
Investors and the media may register for the live webinar here:
https://us02web.zoom.us/webinar/register/WN_Hbu2sP3sSP2M-YI23AXJpg
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a platform technology pioneer in
the field of oral delivery solutions for drugs currently delivered
via injection. Established in 2006, with offices in the United
States and Israel, Oramed has developed a novel Protein
Oral Delivery (POD™) technology. Oramed is seeking to revolutionize
the treatment of diabetes through its proprietary lead
candidate, ORMD-0801, which has the potential to be the first
commercial oral insulin capsule for the treatment of
diabetes. The Company has completed multiple Phase II clinical
trials under an Investigational New Drug application with
the U.S. Food and Drug Administration. In addition, Oramed is
developing an oral GLP-1 (Glucagon-like peptide-1) analog
capsule, ORMD-0901.
For more information, please visit www.oramed.com.
Forward-looking statements: This press release
contains forward-looking statements. For example, we are using
forward-looking statements when we discuss the potential advantages
of Oravax's vaccine candidate and the expected timing to begin
clinical trials, the potential of ORMD-0801 to be the first
commercial oral insulin capsule for the treatment of diabetes or
revolutionizing the treatment of diabetes with our products. In
addition, historic results of scientific research and clinical
trials do not guarantee that the conclusions of future research or
trials will suggest identical or even similar conclusions. These
forward-looking statements are based on the current expectations of
the management of Oramed only, and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements,
including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining
regulatory approval or patent protection for our product
candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to
conduct our research, development and commercialization activities.
In addition, the following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce
new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and finally that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the Securities and Exchange
Commission.
Company Contact
Estee
Yaari
+1-844-9-ORAMED Ext: 2
estee@oramed.com
View original
content:http://www.prnewswire.com/news-releases/oramed-pharmaceuticals-and-oravax-medical-to-be-featured-in-alliance-global-partners-grand-rounds-a-webinar-in-biotech-and-specialty-pharma-301273620.html
SOURCE Oramed Pharmaceuticals Inc.